Ajouter aux favoris   Ajouter cette page à mon bookmark --- SOCIAL BOOKMARKING --- Digg Furl del.icio.us Netscape

Introduction
There is a clear need for new treatments for heart failure, as mortality and morbidity rates, although improving, remain high. Heart failure already represents the leading cause of hospitalization for patients over the age of 65 in Western markets and the aging population in these markets will surely lead to growth in the prevalence of the disease and an increase in healthcare expenditure.

Scope
Assessment of the patient potential, including patient segmentation for developmental chronic and acute heart failure products
Overview of the chronic and acute heart failure R&D pipeline with detailed information on the classes in development
Commercial analysis, supported by the views of key opinion leaders, of key compounds in development in terms of their ability to satisfy unmet needs
Sales forecasts for key late-stage developmental chronic and acute heart failure products in the seven major markets to 2014
Highlights
The late-stage heart failure pipeline is weak in terms of quantity and quality, 81% of products are in Phase I and II of development. The majority of pipeline products are being developed for chronic heart failure with only 33% being developed for acute heart failure.

Developmental chronic heart failure products hold little commercial promise because they are primarily being developed as add-on therapies with niche-focused launch strategies and the increased use of devices in this area form strong competition.

The acute heart failure pipeline has high commercial potential but safety issues have led to disappointment for levosimendan, leaving tolvaptan as the most promising acute heart failure product in the pipeline.

Reasons to Purchase
Gain insight into the current and future prospects for the chronic and acute heart failure market from key opinion leaders
Identify the opportunities and risks for late stage developmental products based on a structured assessment of clinical and commercial attractiveness
View independent sales forecasts for drugs in late-stage development for treatment of chronic and acute heart failure

Introduction
The number of product information sites provided to consumers in the EU is limited, while disease and public education sites are abundant and are used to effectively target consumers, and sites targeting healthcare professionals in the EU are readily available. Sites must be optimized to of influence their target audiences, and to attract, convert and retain these important decision makers.

Reasons to Purchase
Assess and compare the value of 18 leading pharmaceutical companies' web presence across a number of criteria
Identify which tools are needed to encourage European consumers and healthcare professionals to revisit a website and to drive new users to the site
Identify how pharmaceutical companies provide information to European consumers without directly advertising their brand